Sodium DL-malate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 英文名称: Sodium DL-malate
• 英文别名: disodium;2-hydroxybutanedioate
• 化学式: C4H4Na2O5
• 分子量: 178.05
• InChiKey: WPUMTJGUQUYPIV-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -9.75
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Sodium DL-malate 以 水 为溶剂， 以7.8 μL of 4M malic acid aqueous solution obtained的产率得到苹果酸
  参考文献：
  名称：

  Method of immobilizing malate dehydrogenase on a substrate

  摘要：

  将苹果酸脱氢酶固定在底物上，使用含有苹果酸脱氢酶的甘油溶液通过将混合溶液滴入甘油中，混合溶液中至少添加苹果酸和苹果酸盐中的一种，然后在底物上干燥。最好是通过将苹果酸盐添加到含有苹果酸脱氢酶的甘油溶液中来制备混合溶液。苹果酸盐最好是选择钾苹果酸盐和钠苹果酸盐中的至少一种。

  公开号：

  US07521214B2
• 作为产物：
  描述：

  苹果酸 生成 Sodium DL-malate
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Method of introducing amino group and method of synthesizing amino acid compound
  申请人：——

  公开号：US20040162434A1

  公开（公告）日：2004-08-19

  The present invention relates to a method for introducing an amino group into an organic acid or an organic ester by reacting an organic salt or an organic ester and ammonia under high-temperature and high-pressure water conditions, a method for synthesizing an amino acid or an amino ester by the above method, and a method for manufacturing an amino acid compound by synthesizing an amino acid or an amino ester by the above method and separating and refining it with an ion exchange resin.

  本发明涉及一种通过在高温高压水条件下反应有机盐或有机酯和氨来引入氨基到有机酸或有机酯的方法，一种通过上述方法合成氨基酸或氨基酯的方法，以及通过上述方法合成氨基酸或氨基酯并使用离子交换树脂进行分离和精制制造氨基酸化合物的方法。
• Crystalline forms of lamotrigine
  申请人：Hanna Mazen

  公开号：US08486927B2

  公开（公告）日：2013-07-16

  The invention is directed to novel crystalline forms of lamotrigine. These novel crystalline forms of lamotrigine have improved dissolution and in-vivo absorption profile, as compared to pure lamotrigine. These novel crystalline forms of lamotrigine provide a substantial increase in the blood concentration of lamotrigine, as compared to pure lamotrigine when administered to a subject. These novel crystalline forms of lamotrigine also provide a slower, steady build up of lamotrigine blood concentration suitable for sustained release of lamotrigine in-vivo, as compared to pure lamotrigine.

  本发明涉及拉莫三嗪的新型晶体形式。与纯拉莫三嗪相比，这些新型晶体形式具有改善的溶解性和体内吸收特性。当这些新型晶体形式的拉莫三嗪用于治疗对象时，可以显著提高血液中拉莫三嗪的浓度。这些新型晶体形式的拉莫三嗪也提供了适合于体内持续释放的缓慢、稳定的拉莫三嗪血浓度积累，相比之下，纯拉莫三嗪则不具备这种特性。
• Crystal of 5-hydroxy-1H-imidazole-4-carboxamide 3/4 hydrate, method for producing the same and crystal of 5-hydroxy-1H-imidazole-4-carboxamide hydrate
  申请人：FUJIFILM Corporation

  公开号：US09108928B2

  公开（公告）日：2015-08-18

  Provided is a method for producing 5-hydroxy-1H-imidazole-4-carboxamide.3/4 hydrate, including: reacting 2-aminomalonamide with a compound represented by the following formula [1] in the presence of a carboxylic acid to obtain 5-hydroxy-1H-imidazole-4-carboxamide: wherein, in formula [1], each R independently represents a C1-3 alkyl group; reacting the resulting 5-hydroxy-1H-imidazole-4-carboxamide with an acidic compound to obtain a 5-hydroxy-1H-imidazole-4-carboxamide acid salt or a hydrate thereof; and reacting the resulting 5-hydroxy-1H-imidazole-4-carboxamide acid salt or hydrate thereof with a salt in the presence of an acidic solvent to obtain the 5-hydroxy-1H-imidazole-4-carboxamide.3/4 hydrate.

  提供了一种制备5-羟基-1H-咪唑-4-甲酰胺.3/4水合物的方法，包括：在羧酸存在下，将2-氨基马隆酰胺与以下式[1]所代表的化合物反应，以获得5-羟基-1H-咪唑-4-甲酰胺：其中，在式[1]中，每个R独立地表示C1-3烷基；将所得的5-羟基-1H-咪唑-4-甲酰胺与酸性化合物反应，以获得5-羟基-1H-咪唑-4-甲酰胺酸盐或其水合物；将所得的5-羟基-1H-咪唑-4-甲酰胺酸盐或其水合物与盐在酸性溶剂存在下反应，以获得5-羟基-1H-咪唑-4-甲酰胺.3/4水合物。
• CRYSTAL OF 5-HYDROXY-1H-IMIDAZOLE-4-CARBOXAMIDE 3/4 HYDRATE, METHOD FOR PRODUCING THE SAME AND CRYSTAL OF 5-HYDROXY-1H-IMIDAZOLE-4-CARBOXAMIDE HYDRATE
  申请人：FUJIFILM CORPORATION

  公开号：US20150315156A1

  公开（公告）日：2015-11-05

  Provided is a method for producing 5-hydroxy-1H-imidazole-4-carboxamide.3/4 hydrate, including: reacting 2-aminomalonamide with a compound represented by the following formula [1] in the presence of a carboxylic acid to obtain 5-hydroxy-1H-imidazole-4-carboxamide: wherein, in formula [1], each R independently represents a C 1-3 alkyl group; reacting the resulting 5-hydroxy-1H-imidazole-4-carboxamide with an acidic compound to obtain a 5-hydroxy-1H-imidazole-4-carboxamide acid salt or a hydrate thereof; and reacting the resulting 5-hydroxy-1H-imidazole-4-carboxamide acid salt or hydrate thereof with a salt in the presence of an acidic solvent to obtain the 5-hydroxy-1H-imidazole-4-carboxamide.3/4 hydrate.

  提供了一种制备5-羟基-1H-咪唑-4-羧酰胺·3/4水合物的方法，包括：在羧酸存在下，将2-氨基马隆酰胺与下式[1]所表示的化合物反应，以获得5-羟基-1H-咪唑-4-羧酰胺：其中，在式[1]中，每个R独立地表示C1-3烷基基团；将所得的5-羟基-1H-咪唑-4-羧酰胺与酸性化合物反应，以获得5-羟基-1H-咪唑-4-羧酰胺酸盐或其水合物；并在酸性溶剂存在下，将所得的5-羟基-1H-咪唑-4-羧酰胺酸盐或其水合物与盐反应，以获得5-羟基-1H-咪唑-4-羧酰胺·3/4水合物。
• Crystalline Forms of lamotrigine
  申请人：Hanna Mazen

  公开号：US20090176787A1

  公开（公告）日：2009-07-09

  The invention is directed to novel crystalline forms of lamotrigine. These novel crystalline forms of lamotrigine have improved dissolution and in-vivo absorption profile, as compared to pure lamotrigine. These novel crystalline forms of lamotrigine provide a substantial increase in the blood concentration of lamotrigine, as compared to pure lamotrigine when administered to a subject. These novel crystalline forms of lamotrigine also provide a slower, steady build up of lamotrigine blood concentration suitable for sustained release of lamotrigine in-vivo, as compared to pure lamotrigine.

  本发明涉及拉莫三嗪的新型晶体形式。这些拉莫三嗪的新型晶体形式相比纯拉莫三嗪具有更好的溶解和体内吸收特性。这些拉莫三嗪的新型晶体形式在给予受试者时，血液中的拉莫三嗪浓度显著增加，相比纯拉莫三嗪。这些拉莫三嗪的新型晶体形式也提供了更缓慢、稳定的拉莫三嗪血液浓度积累，适用于体内持续释放拉莫三嗪，相比纯拉莫三嗪。

表征谱图